{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:08:15Z","timestamp":1779890895771,"version":"3.53.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetes is significantly associated with cognitive impairment, particularly the risk of developing dementia. However, the impact of antidiabetic drugs on dementia risk remains unclear. This study aims to comprehensively evaluate the effects of different antidiabetic drugs on dementia risk using Bayesian network analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study systematically searched databases including PubMed, Embase, and the Cochrane Library to identify relevant publications up to September 5, 2025. Eligible randomized controlled trials, cohort studies, and case-control studies were selected. We employed a Bayesian network meta-analysis model to quantitatively assess the relationship between antidiabetic drugs and dementia risk. Data analysis was performed using R version 4.4.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 articles (involving 4,382,897 patients), network meta-analysis results indicates that compared with placebo, Insulin [OR = 0.11, 95% CrI (0.1, 0.12)], Metformin [OR = 0.79, 95% CrI (0.77, 0.81)], and Pioglitazone [OR = 0.69, 95% CrI (0.56, 0.86)] all reduced the incidence of dementia compared to placebo, a higher incidence of Alzheimer\u2019s dementia[OR = 1.78, 95% CrI (1.66, 1.91)] and Vascular dementia[OR = 2.59, 95% CrI (2.33, 2.88)] with DPP4i compared to SGLT_2i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study indicate that insulin demonstrates the most pronounced efficacy in reducing the incidence risk of dementia and vascular dementia. Furthermore, SGLT_2i and GLP1 exhibit certain therapeutic benefits in the management of Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251172386.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1780676","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:43:44Z","timestamp":1776228224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pathology and Lab Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangguang","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Shandong Provincial Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106218","DOI":"10.1016\/j.neubiorev.2025.106218","article-title":"Insulin resistance: The role in comorbid type 2 diabetes mellitus and depression","volume":"175","author":"Yao","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713381","article-title":"Advances in research on type 2 diabetes mellitus targets and therapeutic agents","volume":"24","author":"Su","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.dsx.2023.102829","article-title":"Non-sugar sweeteners and health outcomes in adults without diabetes: deciphering the WHO recommendations in the Indian context","volume":"17","author":"Singh","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"B4","article-title":"Type 2 diabetes mellitus and cognitive impairment","volume":"53","author":"Damanik","year":"2021","journal-title":"Acta Med Indones"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-161250","article-title":"Type 1 diabetes mellitus and cognitive impairments: A systematic review","volume":"57","author":"Li","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30118-2","article-title":"Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities","volume":"8","author":"Srikanth","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13850","article-title":"Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer\u2019s Association International conference satellite symposium in Mexico City","volume":"20","author":"Sosa","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Alzheimer\u2019s disease","volume":"167","author":"Soria Lopez","year":"2019","journal-title":"Handb Clin Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms24076518","article-title":"Inflammatory processes in alzheimer\u2019s disease-pathomechanism, diagnosis and treatment: A review","volume":"24","author":"Twarowski","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"123803","DOI":"10.1016\/j.lfs.2025.123803","article-title":"Metformin protects against insulin resistance-related dementia risk involving restored microglial homeostasis","volume":"378","author":"Gonz\u00e1lez P\u00e9rez","year":"2025","journal-title":"Life Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054354","article-title":"Metabolic syndrome as a risk factor for alzheimer\u2019s disease: A focus on insulin resistance","volume":"24","author":"Ezkurdia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241301058","article-title":"Continuous glucose monitoring in comorbid dementia and diabetes: the evidence so far","volume":"20","author":"Donat Ergin","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(24)00120-8","article-title":"Changes in prevalence and incidence of dementia and risk factors for dementia: an analysis from cohort studies","volume":"9","author":"Mukadam","year":"2024","journal-title":"Lancet Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101979","DOI":"10.1016\/j.arr.2023.101979","article-title":"Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"89","author":"Nowell","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"176117","DOI":"10.1016\/j.ejphar.2023.176117","article-title":"Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders","volume":"961","author":"Birajdar","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"123001","DOI":"10.1016\/j.lfs.2024.123001","article-title":"Repurposing antidiabetic drugs for Alzheimer\u2019s disease: A review of preclinical and clinical evidence and overcoming challenges","volume":"355","author":"Tran","year":"2024","journal-title":"Life Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102834","DOI":"10.1016\/j.arr.2025.102834","article-title":"Effects of antidiabetic medications on the relationship between type 2 diabetes mellitus and cognitive impairment","volume":"112","author":"Cozza","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04696-1","article-title":"New insights toward molecular and nanotechnological approaches to antidiabetic agents for Alzheimer\u2019s disease","volume":"478","author":"Pradhan","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411450","article-title":"Repositioning of anti-diabetic drugs against dementia: insight from molecular perspectives to clinical trials","volume":"24","author":"Mantik","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective glucose-lowering agents and dementia risk: A systematic review and meta-analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-019-01220-4","article-title":"The influence of ICAM1 rs5498 on diabetes mellitus risk: evidence from a meta-analysis","volume":"68","author":"Mi","year":"2019","journal-title":"Inflammation Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2024.08.031","article-title":"Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: A systematic review and network meta-analysis with bayesian modeling of treatment histories","volume":"87","author":"Aziz","year":"2025","journal-title":"Eur Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004541","article-title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study","volume":"13","author":"Abdullah","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0222","article-title":"Insulin use in type 2 diabetes and the risk of dementia: A comparative population-based cohort study","volume":"46","author":"Alkabbani","year":"2023","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0783","article-title":"Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial","volume":"42","author":"Biessels","year":"2019","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/jcm9030660","article-title":"Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan","volume":"9","author":"Chen","year":"2020","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.01.007","article-title":"Metformin adherence reduces the risk of dementia in patients with diabetes: A population-based cohort study","volume":"29","author":"Chen","year":"2023","journal-title":"Endocr Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70058","article-title":"Impact of glucagon-like peptide-1 receptor agonists on the dementia incidence in patients with type 2 diabetes mellitus: A population-based longitudinal cohort study","volume":"41","author":"Cheng","year":"2025","journal-title":"Diabetes Metab Res Rev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14336\/AD.2017.1202","article-title":"Metformin and the risk of dementia in type 2 diabetes patients","volume":"10","author":"Chin-Hsiao","year":"2019","journal-title":"Aging Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.01.006","article-title":"Effects of pioglitazone on the incidence of dementia in patients with diabetes","volume":"31","author":"Chou","year":"2017","journal-title":"J Diabetes Complications"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24069","DOI":"10.1038\/s41598-021-03406-5","article-title":"Association of metformin use with Alzheimer\u2019s disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study","volume":"11","author":"Ha","year":"2021","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3220","article-title":"Sodium-glucose cotransporter-2 inhibitors, dulaglutide, and risk for dementia: A population-based cohort study","volume":"177","author":"Hong","year":"2024","journal-title":"Ann Intern Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.diabet.2024.101581","article-title":"Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study","volume":"50","author":"Hong","year":"2024","journal-title":"Diabetes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13131537","article-title":"Association of metformin with the risk of dementia: A population-based retrospective cohort study in Taiwan","volume":"13","author":"Hou","year":"2025","journal-title":"Healthcare (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02648","article-title":"Glucagon-like peptide-1 receptor agonists and incidence of dementia among older adults with type 2 diabetes: A target trial emulation","volume":"178","author":"Inoue","year":"2025","journal-title":"Ann Intern Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"108496","DOI":"10.1016\/j.diabres.2020.108496","article-title":"Metformin use in elderly population with diabetes reduced the risk of dementia in a dose-dependent manner, based on the Korean NHIS-HEALS cohort","volume":"170","author":"Kim","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"B43","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pnpbp.2017.06.002","article-title":"Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus","volume":"79","author":"Kuan","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"112197","DOI":"10.1016\/j.diabres.2025.112197","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients","volume":"224","author":"Liu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-131901","article-title":"Long-term metformin usage and cognitive function among older adults with diabetes","volume":"41","author":"Ng","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004586","article-title":"Metformin vs sulfonylurea use and risk of dementia in US veterans aged \u226565 years with diabetes","volume":"89","author":"Orkaby","year":"2017","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024954","article-title":"Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus","volume":"9","author":"Shi","year":"2019","journal-title":"BMJ Open"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"Bmj-British Med J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad366","article-title":"Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction","volume":"147","author":"Sun","year":"2024","journal-title":"Brain"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2019.0621","article-title":"Dementia risk in type 2 diabetes patients: acarbose use and its joint effects with metformin and pioglitazone","volume":"11","author":"Tseng","year":"2020","journal-title":"Aging Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251351329","article-title":"Associations of semaglutide with Alzheimer\u2019s disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study","volume":"106","author":"Wang","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: A population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13349","article-title":"Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment","volume":"19","author":"Zheng","year":"2023","journal-title":"Alzheimers Dement"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"154887","DOI":"10.1016\/j.phymed.2023.154887","article-title":"Quercetin: A promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis","volume":"126","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251319054","article-title":"Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis","volume":"104","author":"Hui","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.yfrne.2024.101131","article-title":"Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"73","author":"Youn","year":"2024","journal-title":"Front Neuroendocrinol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"9642589","DOI":"10.1155\/2019\/9642589","article-title":"Expression profiles of long noncoding RNAs in intranasal LPS-mediated alzheimer\u2019s disease model in mice","author":"Tang","year":"2019","journal-title":"BioMed Res Int 2019"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"9987","DOI":"10.3390\/ijms22189987","article-title":"Insulin and insulin resistance in alzheimer\u2019s disease","volume":"22","author":"S\u0119dzikowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.neuint.2020.104707","article-title":"Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer\u2019s disease","volume":"135","author":"Akhtar","year":"2020","journal-title":"Neurochem Int"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and alzheimer disease dementia: A randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1243834","article-title":"Astragalus improves intestinal barrier function and immunity by acting on intestinal microbiota to treat T2DM: a research review","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:39:33Z","timestamp":1779889173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":63,"alternative-id":["10.3389\/fendo.2026.1780676"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1780676","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1780676"}}